We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for West Pharmaceutical (WST) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect West Pharmaceutical Services (WST - Free Report) to post quarterly earnings of $1.68 per share in its upcoming report, which indicates a year-over-year increase of 15.9%. Revenues are expected to be $774.47 million, up 11% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain West Pharmaceutical metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales- Contract-Manufactured Products' reaching $144.88 million. The estimate suggests a change of +7.3% year over year.
According to the collective judgment of analysts, 'Net Sales- Proprietary Products' should come in at $624.85 million. The estimate points to a change of +11% from the year-ago quarter.
The average prediction of analysts places 'Gross Profit- Proprietary Products' at $246.34 million. The estimate compares to the year-ago value of $210.20 million.
The combined assessment of analysts suggests that 'Gross Profit- Contract-Manufactured Products' will likely reach $22.31 million. Compared to the present estimate, the company reported $21.70 million in the same quarter last year.
Over the past month, West Pharmaceutical shares have recorded returns of +15.2% versus the Zacks S&P 500 composite's +9.3% change. Based on its Zacks Rank #3 (Hold), WST will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for West Pharmaceutical (WST) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts expect West Pharmaceutical Services (WST - Free Report) to post quarterly earnings of $1.68 per share in its upcoming report, which indicates a year-over-year increase of 15.9%. Revenues are expected to be $774.47 million, up 11% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain West Pharmaceutical metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales- Contract-Manufactured Products' reaching $144.88 million. The estimate suggests a change of +7.3% year over year.
According to the collective judgment of analysts, 'Net Sales- Proprietary Products' should come in at $624.85 million. The estimate points to a change of +11% from the year-ago quarter.
The average prediction of analysts places 'Gross Profit- Proprietary Products' at $246.34 million. The estimate compares to the year-ago value of $210.20 million.
The combined assessment of analysts suggests that 'Gross Profit- Contract-Manufactured Products' will likely reach $22.31 million. Compared to the present estimate, the company reported $21.70 million in the same quarter last year.
View all Key Company Metrics for West Pharmaceutical here>>>Over the past month, West Pharmaceutical shares have recorded returns of +15.2% versus the Zacks S&P 500 composite's +9.3% change. Based on its Zacks Rank #3 (Hold), WST will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .